检验医学 ›› 2015, Vol. 30 ›› Issue (2): 185-190.DOI: 10.3969/j.issn.1673-8640.2015.02.020

• 基础研究·论著 • 上一篇    下一篇

gp96、Mcl-1在肝硬化和肝癌组织中表达及意义

李峰, 魏群, 黄东凤, 张弘   

  1. 南通大学附属医院消化病研究室,江苏 南通 226001
  • 收稿日期:2014-04-22 出版日期:2015-02-28 发布日期:2015-02-12
  • 作者简介:null

    作者简介:李峰,男,1977年生,硕士,主要从事消化系统肿瘤的研究。

    通讯作者:张弘,联系电话:0513-85052461。

Expressions and significance of gp96 and Mcl-1 in liver cirrhosis and hepatocellular carcinoma tissues

LI Feng, WEI Qun, HUANG Dongfeng, ZHANG Hon   

  1. . (Department of Gastroenterology, the Affiliated Hospital of Nantong University, Jiangsu Nantong 226001, China)
  • Received:2014-04-22 Online:2015-02-28 Published:2015-02-12

摘要: 目的

通过研究gp96、髓样细胞白血病-1(Mcl-1)蛋白在肝硬化和肝癌组织中的表达及临床病理学意义,初步探讨其与肝硬化和肝癌发生、发展的关系。

方法

采用免疫组织化学ENVISION法分别检测19例肝硬化组织(癌旁肝硬化组织)、32例肝癌组织和21例对照肝组织(癌旁非硬化肝组织)中gp96、Mcl-1的表达,并分析其各自表达与肝癌临床病理学特征的关系。取来源于同一患者的肝癌组织、癌旁肝硬化组织或癌旁非肝硬化组织,分别配对检测gp96、Mcl-1,比较两者的阳性表达率。

结果

对照组、肝硬化组和肝癌组gp96阳性表达率逐渐递增,差异有统计学意义(P<0.05);gp96的阳性表达与肿瘤有无包膜、TNM分期有关(P<0.05),与患者的性别、年龄、肿瘤大小、血清甲胎蛋白(AFP)值、组织学分级及临床分期无关(P>0.05)。肝癌组和肝硬化组Mcl-1阳性表达率明显高于对照组(P<0.05),但肝癌组和肝硬化组之间差异无统计学意义(P>0.05);Mcl-1阳性表达与肿瘤有无坏死和TNM分期有关(P<0.05)。肝癌组gp96阳性表达率明显高于配对癌旁肝硬化组及配对癌旁非肝硬化组(P均<0.05);而肝癌组Mcl-1阳性表达率明显高于配对癌旁非肝硬化组,与配对癌旁肝硬化组比较差异无统计学意义(P>0.05)。

结论

gp96、Mcl-1过表达可能与肝癌的发生、发展有关。gp96可能参与了肝硬化的发生、发展及向肝癌的恶性转化,有助于判断肝癌患者的预后。

关键词: gp96, 髓样细胞白血病-1, 肝细胞癌, 肝硬化

Abstract: Objective

To investigate the expressions and clinical pathological significance of gp96 and myeloid cell leukemia-1(Mcl-1) in liver cirrhosis and hepatocellular carcinoma tissues to study preliminarily their relationships with the genesis and progression development of liver cirrhosis and hepatocellular carcinoma.

Methods

The expressions of gp96 and Mcl-1 were detected respectively by ENVISION immunohistochemistry in 19 liver cirrhosis tissues (liver cirrhosis tissues beside hepatocellular carcinoma), 32 hepatocellular carcinoma tissues and 21 control tissues (non-liver cirrhosis tissues beside hepatocellular carcinoma). Their relationships of expressions with clinical pathological characteristics of hepatocellular carcinoma were investigated. The expressions of gp96 and Mcl-1 of liver cirrhosis tissues beside hepatocellular carcinoma, hepatocellular carcinoma tissues and non-liver cirrhosis tissues beside hepatocellular carcinoma from one patient were detected, and the positive expression rates were compared.

Results

The positive expression rate of gp96 increased gradually from control, liver cirrhosis to hepatocellular carcinoma groups, which showed significantly different (P<0.05). The positive expression of gp96 had relationships with tumor envelope and TNM staging(P<0.05), and there was no relationship with sex, age, tumor size, serum alpha-fetoprotein (AFP), histological grading and clinical staging (P>0.05). Mcl-1 positive expression in hepatocellular carcinoma and liver cirrhosis groups markedly increased compared to control group, respectively(P<0.05), and there was no statistical significance between liver cirrhosis and hepatocellular carcinoma groups (P>0.05). The positive expression of Mcl-1 had relationships with tumor necrosis and TNM staging(P<0.05). The positive expression rate of gp96 in hepatocellular carcinoma group was significantly higher than those in liver cirrhosis and control groups (P<0.05). The positive expression rate of Mcl-1 in hepatocellular carcinoma group was higher than that in control group, and had no statistical significance with that in liver cirrhosis group (P>0.05).

Conclusions

The overexpressions of gp96 and Mcl-1 are related to the genesis and progression of hepatocellular carcinoma. The gp96 may implicate in the formation and development of liver cirrhosis as well as its subsequent malignant transformation, and may be used as a prognostic biomarker for hepatocellular carcinoma.

Key words: gp96, Myeloid cell leukemia sequence-1, Hepatocellular carcinoma, Liver cirrhosis

中图分类号: